Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford Vaccine Group among winners at NHS Parliamentary awards

Awards & Appointments COVID-19

Researchers behind the Oxford AstraZeneca coronavirus vaccine have been recognised for their excellence at a healthcare awards ceremony.

New book highlights life-saving role vaccines play in prevention of killer diseases

Publication

'Brain Fever', a new book by internationally-renowned medical scientist Professor Richard Moxon, describes the decades of research that contribute to the development of vaccines for life-threatening illnesses such as meningitis, and how immunisation has been our greatest public health intervention.

Mixed Oxford/Pfizer vaccine schedules generate robust immune response against COVID-19, finds Oxford-led study

COVID-19

Alternating doses of the Oxford-AstraZeneca and Pfizer-BioNTech vaccines generate robust immune responses against COVID-19, according to researchers running the University of Oxford-led Com-COV study.

Delayed second dose and third doses of the Oxford-AstraZeneca vaccine lead to heightened immune response

COVID-19 Research

Research on the ChAdOx1 nCoV-19, also known as the Oxford-AstraZeneca vaccine, indicates that a long interval between first and second doses does not compromise the immune response after a late second dose.

First trial participants vaccinated with Oxford COVID-19 variant vaccine

COVID-19

The University of Oxford in partnership with AstraZeneca began vaccinations on 27 June 2021 for a new phase in human trials to test a COVID-19 vaccine ‘AZD2816’ in volunteers against the B.1.351 variant of concern – commonly known as the Beta variant.

Oxford researchers identify levels of antibody protection required to prevent symptomatic COVID-19

COVID-19

Researchers from the University of Oxford have today released their findings about the so-called ‘correlates of protection’ against symptomatic COVID-19; potentially a tool to speed up safe development of new vaccines which may assist regulators in assessing the likely potency of any new COVID-19 vaccine without the need for Phase III efficacy trial data.

Latest data on immune response to COVID-19 reinforces need for vaccination, says Oxford-led study

COVID-19 Publication

A new study led by the University of Oxford has found that previous infection, whether symptomatic or asymptomatic, does not necessarily protect you long-term from COVID-19, particularly against new Variants of Concern.

How do childhood vaccination policies vary across the world?

Publication

Read about the topic in Samantha Vanderslott's latest publication.

OVG's director recognised in Queen’s Birthday Honours

Awards & Appointments

Andrew Pollard, Director of the Oxford Vaccine Group, and Professor of Paediatric Infection and Immunity, becomes a Knight Bachelor for services to Public Health, particularly during the COVID-19 Pandemic.

COVID-19 vaccine messaging that focuses on personal benefits is most effective with those who are hesitant

COVID-19 Public Engagement

For the one in ten who say they won’t take a COVID-19 vaccine, messaging that focuses on personal rather than collective benefits is more effective.

How do nucleic acid vaccines work?

Public Engagement

Ever wondered what happens inside your cells when you are infected with a virus? Or wondered how the new COVID-19 vaccines work? The answer to both of these questions can be found in how our cells receive instructions to make proteins. Actually, our cells are a bit like factories...

Preliminary data suggests mixing Covid-19 vaccine increases reactogenicity

COVID-19

Research, from Com-COV study comparing mixed dosing schedules of Pfizer / Oxford-AstraZeneca vaccines, shows increase in the frequency of mild-moderate symptoms in those receiving either mixed dosing schedule. Adverse reactions were short-lived, with no other safety concerns. Impact of mixed schedules on immunogenicity unknown as yet, with data to follow from this study.

Oxford vaccine professor: rich countries have a moral duty to share their COVID-19 shots

COVID-19

Andrew Pollard writes about vaccine equity in his article for The Conversation.

Increasing vaccine uptake among ethnic minorities

COVID-19 Public Engagement

Dr Samantha Vanderslott and Dr Seilesh Kadambari discuss their collaborative approach to providing ethnic minority groups with information on vaccines.

COVID-19 elimination, not mitigation, best for health, economy and civil liberties – Oxford study

COVID-19

Countries which aimed to eliminate COVID-19 registered fewer deaths, better economic performance, and fewer restrictions and lockdowns, according to an article in The Lancet.

Alternating vaccines trial expands to include two additional vaccines

COVID-19

Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.

UK and EU regulators conclude benefits of vaccination continue to outweigh the risks

COVID-19

Medical regulators in the UK and Europe have announced their conclusions from their reviews of very rare cases of unusual blood clots in people who have received the Oxford-AstraZeneca coronavirus vaccine.

Oxford University researchers release cheap, quick COVID-19 antibody test

COVID-19

The new easy-to-produce test detects coronavirus spike-protein binding antibodies in people who have tested positive for COVID-19.

AstraZeneca publish primary analysis from US trial of coronavirus vaccine

COVID-19

Our partners AstraZeneca have today announced the high-level results from the primary analysis of their Phase III trial of the ChAdOx1 nCoV-19 coronavirus vaccine in the US. They confirm that the vaccine efficacy is consistent with the interim analysis results announced on Monday 22 March 2021.

USA, Chile and Peru interim trial data show Oxford-AstraZeneca vaccine is safe and highly effective

COVID-19

Oxford-AstraZeneca coronavirus vaccine 79% effective against symptomatic COVID-19 overall. Vaccine 100% effective against severe or critical symptomatic COVID-19. No safety concerns reported

Load More